Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage PYRUKYND commercialization in the Gulf Region The SFDA ...
Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision ...
The Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for mitapivat for the treatment of adults with non-transfusion-dependent (NTD) and ...
(WASHINGTON — August 27, 2025) – Treatment with exagamglogene autotemcel (exa-cel) led to robust and sustained improvements in quality of life for patients with severe sickle cell disease (SCD) or ...
On April 22, 2025, the Centers for Disease Control and Prevention informed the National Academy of Sciences that it should terminate all work on this activity. This activity has ended, and a final ...
AMSTERDAM--(BUSINESS WIRE)-- Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results